GeoVax to Present Corporate Update at Noble Capital Markets Conference

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and cancer immunotherapies, announced that Chairman and CEO David Dodd will present at NobleCon21, the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference. The presentation is scheduled for December 3, 2025, at 3:00 pm ET at the Florida Atlantic University Executive Education Complex in Boca Raton, Florida.

The corporate update presentation comes as GeoVax advances multiple clinical programs, including its lead COVID-19 vaccine candidate and oncology therapies. The company's participation in this emerging growth conference signals ongoing investor interest in biotechnology companies developing novel medical solutions, particularly those addressing unmet needs in infectious diseases and cancer treatment.

GeoVax's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. The vaccine is being evaluated as a primary vaccine for immunocompromised patients, including those with hematologic cancers and other populations for whom current authorized COVID-19 vaccines provide insufficient protection. This development is particularly significant given the ongoing challenges in protecting vulnerable populations against COVID-19 variants and the limitations of existing vaccine platforms for immunocompromised individuals.

Additional trials are examining GEO-CM04S1 as a booster vaccine in patients with chronic lymphocytic leukemia and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. The pursuit of enhanced durability and broader protection addresses critical gaps in current COVID-19 vaccination strategies, potentially offering longer-lasting immunity and better protection for high-risk groups.

In oncology, GeoVax's lead program involves Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The development of innovative cancer immunotherapies represents an important advancement in treating solid tumors, which remain challenging to address with conventional therapies.

The company is also developing a vaccine targeting Mpox and smallpox, and based on recent regulatory guidance, anticipates progressing directly to Phase 3 clinical evaluation, bypassing Phase 1 and Phase 2 trials. This accelerated pathway could significantly shorten the development timeline for a crucial biodefense and public health vaccine.

Interested investors and guests can register for the conference at a discounted rate using code GOVXNOBLECON. A high-definition video webcast of the presentation will be available the following day through Noble Capital Markets' conference website at https://www.nobleconference.com and on Channelchek at https://www.channelchek.com. The webcast will remain archived for 90 days following the event. Senior GeoVax management will also conduct one-on-one meetings with registered attendees during the conference.

For additional information about the company's clinical trials and technology developments, visit https://www.geovax.com. The presentation at NobleCon21 provides investors and the medical community with important updates on GeoVax's progress in developing solutions for significant public health challenges, including COVID-19 protection for vulnerable populations and innovative cancer treatments.